In our study, subgroup analysis of the use of immune-modifying therapies in our population revealed that the use of systemic steroids and a composite of immune-modifying therapies (steroids, anti-TNF, JAK inhibitors, azathioprine, and methotrexate) represented a higher risk of RSV infection in the IBD-SARS-CoV-2 cohort than in the control group. Here, TNF is linked to inflammatory bowel disease.